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Abstract 
In recent years, a paradigm shift from single-photon-emitting radionuclide radiotracers toward 
positron-emission tomography (PET) radiotracers has occurred in nuclear oncology. Although 
PET-based molecular imaging of the kidneys is still in its infancy, such a trend has emerged in the field of 
functional renal radionuclide imaging. Potentially allowing for precise and thorough evaluation of renal 
radiotracer urodynamics, PET radionuclide imaging has numerous advantages including precise 
anatomical co-registration with CT images and dynamic three-dimensional imaging capability. In addition, 
relative to scintigraphic approaches, PET can allow for significantly reduced scan time enabling 
high-throughput in a busy PET practice and further reduces radiation exposure, which may have a clinical 
impact in pediatric populations. In recent years, multiple renal PET radiotracers labeled with 11C, 68Ga, 
and 18F have been utilized in clinical studies. Beyond providing a precise non-invasive read-out of renal 
function, such radiotracers may also be used to assess renal inflammation. This manuscript will provide an 
overview of renal molecular PET imaging and will highlight the transformation of conventional 
scintigraphy of the kidneys toward novel, high-resolution PET imaging for assessing renal function. In 
addition, future applications will be introduced, e.g. by transferring the concept of molecular 
image-guided diagnostics and therapy (theranostics) to the field of nephrology. 
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Introduction 
Renal functional imaging with single-photon- 
emitting radiotracers has been used as a noninvasive 
diagnostic technique since the mid-1960s [1], and, 
during that time, three categories for renal 
radionuclide scintigraphy have been established 
(Figure 1). These are (1) radiotracers that are mainly 
filtered by the glomerulus to monitor glomerular 
filtration rate (GFR); (2) radiotracers that undergo 
tubular secretion for the measurement of effective 
renal plasma flow (ERPF); and (3), radiotracers that 
are taken up into the tubules so that morphological 
and/or tubular uptake function can be assessed 










Figure 1. First renal scintigraphy with Chlormerodrin (203Hg), showing (A) rather less clear images shortly after transplantation, while in a long-term follow-up after 63 days (B), a 
“great improvement in the renal contours“ was noted by Figueroa et al [1]. Red arrows indicate uptake in the bladder. In (C), a renal scan of patient 5 days after transplantation is displayed 
and the scan showed “negative contrast” with almost no uptake in the kidney. The patient died 8 days later. Adapted with permission from [1], copyright 1965 NEJM Massachusetts Medical 
Society. 
Table 1. Characteristics of renal scintigraphy along with clinical indications. 
Categories Filtered by the glomerulus Secreted by the tubules Tubular fixation 
Single photon radiotracers 99mTc-DTPA 99mTc-MAG3 99mTc-DMSA 
Main indication Measurement of GFR Measurement of ERPF Morphological assessment 
Alternate in clinical practice Serum creatinine, Creatinine clearance, Inulin clearance PAH Clearance Ultrasound, etc. 
Other clinical indication Obstructive uropathy, Renal transplant rejection, Renovascular hypertension Pyelonephritis and parenchymal scarring 
DTPA: diethylenetriaminepentaacetic acid, MAG3: mercaptoacetyltriglycine, DMSA: dimercaptosuccinic acid, GFR: glomerular filtration rate, ERPF: effective renal plasma 
flow, PAH: p-aminohippurate. 
 
 
Figure 2. Different mechanisms of renal radiotracer uptake and excretion. 
EDTA: ethylenediaminetetraacetic acid, DTPA: diethylenetriaminepentaacetic acid, NOTA: 
1,4,7-Triazacyclononane-1,4,7-triacetic acid, FDS: 2-deoxy-2-fluoro-D-glucose, PAH: 
p-aminohippurate, OIH: orthoidodohippurate, MAG3: mercaptoacetyltriglycine, 
Re(CO)3FEDA: Re(CO)3-N-(fluoroethyl)iminodiacetic acid, PABA: para-aminobenzoic 
acid, DMSA: dimercaptosuccinic acid. 
 
Over the last decades, other imaging modalities 
for assessing renal function beyond renal 
radionuclide imaging have emerged and include, but 
are not limited to, ultrasound, computed tomography 
(CT), and magnetic resonance imaging (MRI). 
Ultrasound provides a fast and easily obtainable 
read-out of kidney morphology, while computed 
tomography (CT)-angiography provides in-depth 
renal vascular information. Renal MRI (rMRI), 
however, provides information with superior 
soft-tissue contrast to characterize renal masses or 
parameters on renal flow [3, 4]. Due to the increased 
use of those imaging modalities, the use of renal 
scintigraphy has significantly decreased 
(approximately 25%) in the last decade [5, 6]. Given its 
unique feature to reliably assess spilt renal function, 
renal scintigraphy is still frequently requested by 
referring physicians, especially for pediatric 
populations or for evaluating living donors for kidney 
transplantation [7]. Table 2 provides an overview of 
advantages and disadvantages for different imaging 
modalities used for renal functional imaging. 
Recent years have also witnessed a shift from 
single-photon emission computed tomography 
(SPECT) to higher-resolution positron emission 
tomography (PET), which is supported by the 
overwhelming success and increased availability of 
PET imaging for oncological applications [8]. Of note, 
various PET radiotracers have been evaluated to 
assess renal function, such as 68Ga-ethylene-
diaminetetraacetic acid (68Ga-EDTA), 11C-para- 
aminobenzoic acid (11C-PABA) and 2-deoxy-2- 
[18F]fluoro-D-sorbitol (18F-FDS) [9-15]. In addition, the 
field of renal nuclear imaging has been further 
expanded by assessing urinary tract infections [16]. 
The resulting refinements relative to SPECT may find 
growing applications for such highly specific renal 





PET-based imaging approaches. This review article 
will provide an overview of renal molecular PET 
imaging and will highlight the transformation of 
conventional scintigraphy of the kidneys toward 
novel, higher-resolution PET imaging for assessing 
renal function. In addition, future applications in 
clinical practice will be introduced, e.g. by applying 
non-invasive systemic read-outs for assessing 
kidney-organ crosstalk or by transferring the concept 
of molecular image-guided diagnostics and therapy 
(theranostics) from oncology to the field of 
nephrology.  
Dynamic renal scintigraphy with single- 
photon-emitting radiotracers 
The most important quantitative characteristics 
for renal function are GFR and ERPF, and the gold 
standard for measuring both biomarkers is the 
clearance of exogenous substances, such as inulin and 
para-aminohippuate. Given the expensive and 
time-consuming nature of these diagnostics tests, they 
are nowadays seldomly performed. Normally, the 
kidneys receive 20% of cardiac output, with renal 
plasma flow averaging 600mL/min. The kidneys clear 
waste products and other substances from the plasma, 
and their clearances are determined by both 
glomerular filtration and tubular secretion. GFR is 
defined as the volume of filtrate by both kidneys per 
minute and is normally approximately 125 mL/min, 
i.e. 20 % of renal plasma flow delivered to the kidneys. 
A decline in GFR to <60 mL/min/1.73 m2 for ≥3 
months is a common criterion for defining chronic 
kidney disease and such a loss in GFR has been well 
associated with a higher risk of all-cause mortality 
[17]. In current clinical practice, GFR is estimated 
using serum creatinine, but that approach lacks 
precision [18, 19]. 51Cr-labeled ethylenediamine-
tetraacetic acid (EDTA) and 125I-labeled iothalamate 
are radiolabeled exogenous substances that offer more 
precise measurements of GFR, but are rarely used in 
currently clinical practice because of high costs and 
inability to provide split renal function [9, 11, 20]. On 
the other hand, the true renal plasma flow cannot be 
calculated because no substance undergoes 100% 
first-pass extraction. The clearance of substances that 
are almost completely extracted include 
para-aminohippuate (PAH) or ortho-iodohippurate 
(OIH), which are 20% filtered by the glomerulus and 
80% secreted in the tubules. As a result, effective renal 
plasma flow (ERPF) is used as a biomarker in clinical 
practice [21, 22]. There is no blood marker to estimate 
ERPF, and clearance of PAH or radiolabeled OIH was 
used to measure ERPF, but similar to inulin clearance 
in GFR, this approach is not well established in 
clinical practice [9]. 
 
Table 2. Head-to-head comparison of different image modalities for assessing renal function. 
Imaging 
Modality 
MRI CT Ultrasound PET 
Advantages Allows for precise tissue 
differentiation [88]  
Can examine various physiologic 
aspects of renal function (perfusion, 
glomerular filtration, interstitial 
diffusion, tissue oxygenation, tubular 
transit) [88] 
MR renography can reliably diagnose 
renovascular hypertension, urinary 
obstruction or renal transplant 
complications [88] 
Assessment of split-renal function [89] 
Better arterial input functions and 
separation in duplicate kidneys 
relative to PET [89] 
Can compensate motion (kidneys are 
prone to motion artefacts given their 
anatomical localization under the 
diaphragm) [89] 
Widely available 
Various clinical applications, 
including staging/restaging, 
obstruction (kidney stones, polycystic 
kidney disease) 
Localizing of abscesses 
Preoperative planning prior to partial 
nephrectomy [89] 
Virtually available at 
every hospital [90] 
Low costs [90] 
No need for intravenous 
iodine contrast 
adminis-tration [90] 
Fast read-out of kidneys 
and adjacent organs, e.g. 
for renal cyst evaluation 
 
Large variety of renal function can be 
assessed, e.g. GFR, ERPF, 
inflammation, RBF or renal PSMA 
expression  
3-dimensional read-out capabilities 
Assessment of split-renal function  
1mSv radiation exposure [89] 
No pharmalogical effects [89] 
Can be used in a theranostic setting, 
e.g, for RCC or to assess organ-organ 
interactions 
 
Disadvantages Confined space and loud noises 
leading to patient discomfort 
Certain devices, such as pacemakers, 
are harmful  
Risk of nephrogenic systemic fibrosis 
with MRI contrast agents [91] 
Spatial resolution is limited as only 
multiple 2D slices are provided [89] 
Life-threatening contrast-induced 
nephropathy with CT contrast agents 
[91] 
Anaphylactoid reactions 
CT contrast media may lead to 
drug-drug interactions, e.g. 
increasing the retention of metformin 
leading to lactic acidosis [91] 
Radiation exposure (up to 8 mSv) [89] 
Spatial resolution is 
limited with single 2D 
slices [89] 
Does not provide detailed 
functional information 
PET radionuclides emit all the same 
energy photons at 511keV and 
therefore, it is not feasible to use 
multiple PET tracers at the same time 
[89] 
No larger clinical trials to date  
No FDA approval to date for PET 
radiotracers evaluating renal 
function 
MRI: magnetic resonance imaging, CT: computed tomography, PET: positron emission tomography, GFR: glomerular filtration rate, ERPF: ERPF: effective renal plasma 
flow, PSMA: prostate-specific membrane antigen, FDA: Food and Drug Administration. 
 





Table 3. Characteristics of positron emitters. 
 11C 18F 68Ga 
Half-life (min) 20 110 68 
Production source on site cyclotron on site cyclotron or delivery 68Ge/68GaGenerator 
Positron energy (MeV) 0.96 0.64 1.90 
Positron range (mm) 1.1 1.0 2.9 






Advantage Less exposure to radiation Lower cost 
Delivery available 
Flexibility due to longer half-life 
Physical properties suitable for imaging 
Can be operated without a cyclotron 
PABA: para-aminobenzoic acid, FDS: 2-deoxy-2-fluoro-D-glucose, PFH: p-fluorohippurate Re(CO)3FEDA: Re(CO)3-N-(fluoroethyl)iminodiacetic acid, EDTA: 
ethylenediaminetetraacetic acid, NOTA: 1,4,7-Triazacyclononane-1,4,7-triacetic acid. 
 
 
Instead of blood clearance of exogenous 
substances, dynamic renal scintigraphy with 
99mTc-diethylenetriaminepentaacetic acid (99mTc- 
DTPA; GFR radiotracer) and 99mTc-mercaptoacetyl-
triglycine (99mTc-MAG3; ERPF radiotracer) is 
routinely performed to provide comprehensive 
information about the kidney. Due to its high 
accumulation and low background accumulation, 
99mTc-MAG3 allows for high contrast renal images [2, 
18]. 99mTc-DTPA can provide an assessment of GFR 
because of its nature of radiotracer filtration at the 
glomerulus and minimal tubular uptake [2]. The 
advantages of such renal scintigraphy include 
measurement of renal function along with 
comprehensive assessment of the entire urinary 
excretion system, including both kidneys and ureters. 
Furthermore, these techniques can be used in patients 
with poor renal function who are not eligible for 
CT-based contrast enhanced imaging. As a major 
advantage, radiation exposure is lower relative to CT, 
rendering these techniques as attractive kidney 
functional read-outs in pediatric populations, in 
particular for repeated renal studies [23]. 
As a major drawback, renal scintigraphy has 
only limited spatial resolution of > 1cm when 
compared with other imaging modalities. Assessment 
is mainly based on planar dynamic images. Compton 
scatter and soft-tissue attenuation can further reduce 
the image resolution as well as quantification 
reliability [9, 11]. The combination of SPECT and CT 
(SPECT/CT) can be used for soft tissue attenuation 
correction using CT attenuation map [9, 11], although 
this adds significantly to the radiation exposure and 
lacks the temporal resolution of planar imaging. The 
recently introduced high-end cadmium-zinc-telluride 
(CZT) cameras have even better energy resolution 
which may further reduce scatter artifacts [24]. 
Comparison of PET and conventional renal 
nuclear imaging 
In contrast to scintigraphy with single-photon- 
emitting radiotracers, PET provides multiple 
advantages including high temporal resolution and 
sensitivity allowing dynamic three- 
dimensional acquisition, superior spatiotemporal 
resolution, absolute quantification with radiotracer 
kinetics modeling and three-dimensional 
co-registration with CT images. PET imaging for 
assessment of the urinary tract using standard 
scanners with an axial field of view of 20 cm cannot 
cover the entire urinary system in a single field of 
view for a continuous three-dimensional dynamic san 
[9, 25]. Recently introduced large axial view PET 
scanners such as the total-body PET Explorer, 
however, can image the entire body with one bed 
position (axial field of view 194 cm) and thus, such 
novel scanners may allow for imaging the entire 
urinary tract using dynamic acquisition [26].  
Positron emitting radionuclides 
Various positron-emitting radionuclides have 
been used clinically and their characteristics are 
defined by different half-lives of the isotope, positron 
range, and production source (Table 3). 18F and 11C, 
recognized as common standard PET isotopes, are 
synthesized by a cyclotron, whereas 68Ga is typically 
produced by a generator. Longer half-life of 18F (110 
min) is a major advantage as it allows radiotracer 
delivery from central cyclotron facilities and 
flexibility in study design in clinical practice (e.g. 
delayed imaging protocols). Because of its shorter 
half-life (20min), 11C-labeled radiotracers are difficult 
to use in clinical routine [27]. On the other hand, 68Ga 
has a relatively longer half-life (68 min) but it requires 
an in-house 68Ge/68Ga generator [28]. Since 
68Ga-labeled radiotracers for somatostatin- 
receptor (SSTR) and prostate-specific membrane 
antigen (PSMA) imaging for neuroendocrine tumors 
and prostate cancer are frequently used in the clinic, 
the availability of such generators has improved [29]. 
68Ga, however, has a relatively high positron energy 
with long positron range when compared to 18F which 
results in reduced spatial resolution [28, 29]. 
Moreover, in nuclear oncology, there is a shift from 





68Ga to 18F-labeled radiotracers and one may speculate 
that this trend will also further fuel the development 
and increased clinical use of 18F radiotracers for renal 
radionuclide imaging [8]. 
GFR agents 
68Ga-ethylenediaminetetraacetic acid (EDTA) 
68Ga-EDTA reflects GFR, and is the only renal 
imaging agent to date that has been evaluated in a 
large clinical trial. Of note, 68Ga-EDTA has been 
validated since the 1960s, before the widespread use 
of PET [30, 31]. Physiologically stable metal chelates 
like EDTA are excreted by glomerular filtration and, 
until recently, were widely used for the quantitative 
assessment of GFR by using 51Cr-EDTA. Later, with 
the development of gamma cameras, 99mTc-labeled 
renal radiotracers became the main focus of research. 
With the increased availability of PET imaging in the 
past two decades, 68Ga-based PET imaging of the 
kidneys has reemerged [11].  
Hicks et al. first revealed the excellent kinetics of 
68Ga-EDTA as a renal radiotracer in small animal 
studies [32], and then investigated the agent in 
humans [10]. 68Ga-EDTA initially concentrates in the 
blood pool, promptly begins to accumulate in the 
renal cortex, transfers to the renal parenchyma and 
further into the collecting system 3-4 minutes after 
administration. In a study of 31 patients with different 
degrees of kidney function, ranging from severely 
impaired to normal, Hofman et al. calculated GFR 
from PET images of 68Ga-EDTA as well as compared 
the results with GFR from 68Ga-EDTA and 51Cr-EDTA 
plasma sampling. The GFR measured by 68Ga-EDTA 
and 51Cr-EDTA plasma sampling showed an excellent 
correlation (Pearson correlation coefficient of 0.94). 
GFR quantified by 68Ga-EDTA clearance derived from 
three organ compartments including the kidneys, 
ureter and the bladder correlated well with GFR from 
plasma sampling (correlation co-efficient 0.9). In 
subjects with a 51Cr-EDTA GFR of more than 150 
mL/min, 68Ga-GFR was significantly lower and the 
authors explained such findings by plasma binding, 
tubular secretion, or dissociation in vivo. Furthermore, 
in 11 patients, 99mTc-dimercaptosuccinic acid 
(99mTc-DMSA) was conducted and read-out included 
a renal static scintigraphy approach, planar imaging, 
and SPECT/CT. Good agreement between 
99mTc-DMSA SPECT/CT and excretory phase (2-10 
minutes) from 68Ga-EDTA dynamic PET was noted. 
The latter imaging modality, however, allows more 
in-depth information on the entire urinary tract 
system in a 3-D capability relative to SPECT [10, 11]. 
68Ga-1,4,7-Triazacyclononane-1,4,7-triacetic acid 
(68Ga-NOTA) 
68Ga-NOTA is a 68Ga-labeled metal chelate 
whose clearance reflects GFR, similar to 68Ga-EDTA. 
Lee et al. measured serum protein binding of 
68Ga-NOTA and performed small animal PET studies 
for comparison with 51Cr-EDTA. 68Ga-NOTA showed 
the lowest serum protein binding compared to the 
other 68Ga-labeled chelating agents (DOTA, DTPA 
and EDTA). Furthermore, both 68Ga-NOTA and 51Cr- 
EDTA showed very similar biodistribution patterns 
and almost the same GFR [33]. Although it is likely 
that their results can be replicated in humans, further 
studies in patients are needed. 
68Ga-IRDye800-tilmanocept 
Another GFR-reflecting agent, radiolabeled 
tilmanocept has been reported as a unique radiotracer 
for evaluating diabetic nephropathy. The number of 
diabetic patients continues to increase, with diabetic 
nephropathy being the leading cause of chronic renal 
failure and occurring in 40% [34]. In such patients, 
nephropathy progresses slowly over 20 to 30 years, 
with no symptoms or decline in kidney function in 
early stages. GFR decline occurs predominantly in 
advanced nephropathy, which highlights the urgent 
need to develop imaging tests providing reliable 
information on the progression of the disease. Qin et 
al. investigated radiolabeled tilmanocept imaging in 
mice and its colocalization in the glomerulus with 
histologic examination. PET imaging of 
68Ga-IRDye800-tilmanocept demonstrated receptor- 
mediated renal accumulation with evidence of 
glomerular uptake. Histologic examination 
demonstrated colocalization of CD206 which resides 
on the surface of mesangial cells, and 
IRDye800-tilmanocept within the glomerulus. 
Furthermore, molecular imaging of diabetic and 
nondiabetic mice was performed with fluorescence- 
labeled 99mTc-tilmanocept, and hyperfiltration of 
tilmanocept was observed in diabetic mice. Given the 
important role of mesangial cells during the 
progression of diabetic nephropathy, PET or SPECT 
renal imaging with radiolabeled tilmanocept may 
provide noninvasive quantitative assessment of 
glomerular function even in early disease stages [35]. 
18F-FDS 
18F-FDS, which is a sorbitol derivative filtered 
through the glomerulus, has shown excellent 
pharmacokinetics and is readily available by a simple 
one-step synthesis from the most commonly used 
radiotracer 18F-FDG. This makes it available at 
virtually every PET practice with access to, or supply 
by, a cyclotron facility [36]. In early human studies, 





urinary clearance of sorbitol was reported to be 
identical to that of inulin (sorbitol–to–inulin clearance 
ratio = 1.01) [37]. Hence, 18F-FDS, an analogue of 
sorbitol, may have similar kinetics as inulin, with free 
filtration at the renal glomerulus and no tubular 
reabsorption. 
To explore the potential of 18F-FDS as a renal PET 
radiotracer, basic biodistribution properties and 
clearance through the renal collecting system 
pathway were explored in healthy rats. Dynamic PET 
imaging showed rapid accumulation in the kidneys 
followed by a time-dependent transition to the 
collecting system. There was almost no accumulation 
of background, such as liver, intestines and spleen, 
suggesting low hepatobiliary clearance and exclusive 
renal filtration of 18F-FDS. PET renography showed 
cortical accumulation in the initial blood flow phase 
and subsequent rapid parenchyma and transfer of the 
radiotracer to the collecting system. Split renal 
function assessment demonstrated a normal 
renogram pattern. Accumulation in the cortex in the 
early blood flow phase was confirmed by ex vivo 
autoradiography. Comparable renal distribution of 
18F-FDS and 99mTc-DTPA was achieved in the identical 
animal after dual radiotracer administration. 
Postmortem tissue analysis showed that 18F-FDS had 
the highest accumulation in the kidneys at all imaging 
time points. Radio–thin-layer chromatography 
analysis also demonstrated that no radioactive 
metabolites were detected in blood and urine 35 
minutes after radiotracer administration. 
Furthermore, in vivo serum protein binding of 18F-FDS 
was less than 0.1% at 35 minutes after radiotracer 
administration [13]. Only the free fraction of the 
radiotracer is filtered at the glomerulus and protein 
binding in the blood leads to underestimation of the 
GFR. The protein binding of 99mTc-DTPA has been 
reported to range from 2% to 10% [38, 39] and the 
100-fold lower serum binding properties of 18F-FDS 
indicate that 18F-FDS is not only an excellent GFR 
substance with excellent pharmacokinetics similar to 
the gold standard inulin, but also has a substantially 
higher stability in the blood relative to its SPECT 
counterpart. 
Based on these preclinical results, the potential of 
18F-FDS as a functional renal imaging agent has been 
investigated using two different rat models of acute 
renal failure (ARF) and unilateral ureteral obstruction 
(UUO). On PET images, ARF rats, induced by 
intramuscular injection of glycerol, had significantly 
less uptake in the renal cortex and slower excretion 
into the bladder than controls. Furthermore, the 
renogram presented a non-functional pattern. In UUO 
rats, obtained by complete ligation of the left ureter 
near the renal pelvis, lower and delayed uptake was 
observed on the obstructed left side, with no 
transition into the collecting system, whereas the 
contralateral side showed results similar to those 
obtained in control rats. Renograms showed that the 
UUO collecting system presented a typical obstructed 
pattern [15]. These results indicate the potential of 
18F-FDS as a radiotracer providing a non-invasive 
read-out of the urinary tract that may also allow for 
precise GFR measurements. 
Dynamic 18F-FDS PET was performed in two 
healthy human volunteers [14]. The renal cortex was 
first delineated and activity gradually transited in the 
parenchyma, followed by radiotracer excretion 
(Figure 3). The kidneys had the highest radiotracer 
accumulation after the initial blood phase. Due to the 
higher resolution of the PET images, it was possible to 
contour three-dimensional volumes of interest on 
both cortical and medullary segments and obtain time 
activity curves (Figure 3) [14]. Compared to 
conventional scintigraphy, PET/CT information 
along with 3D data may allow for a more accurate 
analysis of renal function independent of background 
accumulation, renal malformations, and rotation. As 
alluded to earlier, 18F has a higher positron yield (18F, 
96.86% vs 68Ga, 89.14%) and lower positron energy 
(18F, 633 keV vs 68Ga, 1,899 keV) which increases 
diagnostic yield relative to 68Ga [8]. Although the 
first-in-human results are encouraging [14], the 
protocol needs to be refined and validated in a larger 
number of patients to confirm these preliminary 
findings. 
68Ga-PSMA-11 
Recently, split renal function has been evaluated 
by a 68Ga-labeled prostate-specific membrane antigen 
(PSMA) PET imaging agent. When compared to 
99mTc-MAG3 in 97 prostate cancer patients, high 
correlation indices for assessing split renal function 
between both techniques could be achieved [40]. 
68Ga-Ga-HBED-CC-DiAsp 
 68Ga-Ga-HBED-CC-DiAsp (Di-Aspartic acid 
derivative of N,N'-bis [2-hydroxy-5-(carboxyethyl)-
benzyl]-ethylenediamine-N,N'-diacetic acid) is a 
kit-based radiotracer, that potentially exhibits a 
higher stability when compared to 68Ga-EDTA, 
rendering it as a potential diagnostic agent to assess 
GFR in-vivo. In a rat study, biodistribution and 
dynamic PET/CT imaging studies in rats revealed a 
rapid clearance [41].  
ERPF agents 
p-[18F]Fluorohippurate (18F-PFH) 
18F-PFH reflects ERPF and may predict the 
longterm prognosis of the kidney as demonstrated in 





animal studies [42]. The molecular structure of 
18F-PFH is similar to that of p-aminohippurate, a gold 
standard for the measurement of ERPF. Awasthi et al. 
reported the synthesis and initial in vivo evaluation of 
18F-PFH in a rat model. Dynamic PET revealed a rapid 
clearance of 18F-PFH through the renal–urinary 
pathway [43]. In light of these encouraging findings, 
Pathuri et al. compared the renogram of 18F-PFH with 
125I-OIH as a gold standard, and with a clinically used 
agent (99mTc-MAG3), in healthy rats. The results 
showed no significant difference in time-to-peak, but 
in the visual analysis of renograms, 18F-PFH seemed 
to be closer to 125I-OIH compared to 99mTc-MAG3. In 
addition, the quality of the renogram and the images 
obtained with the dynamic 18F-PFH PET study were 
remarkably better than those obtained with the 
99mTc-MAG3 dynamic planar imaging study [44]. 
Additionally, the same research group evaluated the 
potential of early 18F-PFH PET renography to predict 
future progression of PKD in Han:SPRD rats with 
slowly progressive autosomal dominant PKD. They 
obtained T2 and T20 values, which represent the 
percentage of the injected dose of 18F-PFH in kidneys 
at 2 and 20 min after injection, from the imaging data 
and assessed T20/T2 ratio as a prognostic marker. 
T20/T2 values at 6 weeks correlated with serum 
creatinine, serum urea nitrogen, and kidney weight 
per body weight at 26 weeks. These results 
demonstrated 18F-PFH could be a surrogate marker, 
e.g. for progression of autosomal dominant 
polycycstic kidney disease [42]. 
Re(CO)3(18F-FEDA) 
Re(CO)3(18F-FEDA) is an ERPF agent, and can be 
labeled with either 99mTc or 18F, depending on the 
application. Lipowska et al. demonstrated that 
99mTc-Re(CO)3(FEDA) had comparable pharmaco-
kinetics to 131I-OIH in rats [45] and its 18F-labeled 
counterpart exhibited a high specificity for the 
kidneys along with rapid renal excretion and high in 
vitro and in vivo stability comparable to those of its 
99mTc-labeled analogue [46].  
11C-PABA 
Most recently, Ruiz-Bedoya et al. investigated 
11C-PABA as a new PET renal agent. PABA is a 
non-toxic B-complex vitamin with fast renal excretion, 
and has been previously used to assess 24-hour urine 
tests. One of its main metabolites, para-aminohippuric 
acid, has been defined as a gold standard to measure 
ERPF due to its high renal tubular secretion and thus, 
11C-PABA may provide reliable information on ERPF. 
The authors confirmed the pharmacokinetics of 
11C-PABA in rats and rabbits with dynamic PET, and 
performed first-in-human PET imaging studies in 
healthy volunteers. Dynamic PET demonstrated a 
rapid accumulation of 11C-PABA in the renal cortex, 
followed by rapid excretion through the pelvicalyceal 
system with low background signal from other organs 
in rats and rabbits. In humans, the cortex was 
delineated on PET, and the activity gradually shifted 
to the medulla and renal pelvis with high 
spatiotemporal resolution. In addition, the 
biodistribution of 11C-PABA and 99mTc-MAG3 in 
postmortem tissues were directly compared by 
measuring organ-associated radioactivity 30 minutes 
after simultaneous injection of both radiotracers in 
identical rats. The results revealed a lower 
background activity in normal tissue for 11C-PABA 
compared to 99mTc-MAG3. Moreover, relative to 
99mTc-MAG3, a human dose analysis based on mouse 
data for 11C-PABA showed that the latter radiotracer 
had a 1.6-fold lower dose. Although the short half-life 
requires an on-site cyclotron, which increases costs, 
the authors concluded that 11C-PABA could be used 
as a novel radiotracer for functional renal imaging, 
providing high-quality spatiotemporal images with 
low radiation exposure, rendering 11C-PABA as a 
suitable imaging agent for pediatric populations [12]. 
Figure 4 provides an overview of renal imaging using 
11C-PABA.  
GFR and ERPF Assessments 
18F-FDG 
Attempts to calculate renal function using 
18F-FDG, which is most commonly used in daily 
clinical practice, have also been reported. Although it 
appears demanding to obtain information about renal 
function from a substance like 18F-FDG which is 
involved in various physiological processes, such an 
approach would be of great benefit, in particular as 
information on renal function could be obtained in 
addition to other clinical applications, e.g. tumor 
staging. In this regard, Geist et al. performed dynamic 
18F-FDG-PET/MRI and Patlak analysis to determine 
GFR and ERPF in 24 healthy volunteers. Using 
blood-based creatinine clearance and the 99mTc-MAG3 
tubular extraction rate as a reference, total kidney 
GFR and ERPF as estimated by dynamic PET/MRI 
were highly correlated when compared to the 
reference standard (r=0.82-0.88) [47]. Apart from 
18F-FDG, 11C-acetate PET/CT may also provide 
human glomerular filtration rate based on 
compartmental modeling [48]. 
Renal Blood Flow 
Several radiotracers have been introduced for 
assessing renal blood flow (RBF). For instance, H215O, 
which is freely diffusible between tissue and blood, 
has been investigated in patients with renal 





dysfunction demonstrating significantly lower flow 
values when normalized to 100 g of tissue measured 
with H215O when compared to healthy individuals 
(Figure 5) [49]. Owing to its short half-life of 2.1 min, 
more practical radiopharmaceuticals for reliably 
assessing RBF are intensively sought. In this regard, 
another class of RBF measuring agents has penetrated 
the clinical arenas, which are physiologically retained 
in renal tissue [50]. Among others, 82Rubidium (82Rb) 
has a high first pass extraction and slow renal 
washout rendering it as an ideal imaging agent to 
measure RBF. Tamaki et al investigated 82Rb in dogs 
using a steady-state kinetic model with various 
degrees of kidney injury and concluded that 82Rb 
allows for serial quantitative assessment of RBF [51]. 
This has been further evaluated for clinical use by 
investigating healthy volunteers showing that 
non-invasive quantitative imaging with 82Rb is 
feasible, allowing for excellent image quality, high 
resolution and contrast [52]. In addition, this 
radiotracer is a potassium analogue and therefore, a 
recent report also demonstrated that renal potassium 
excretion can be visualized by 82Rb PET [53]. 
Moreover, 13N-ammonia, which is widely utilized for 
myocardial perfusion imaging [54], has been also 
investigated to quantify RBF [55], which paves the 
way for assessing cardiorenal perfusion crosstalk. Of 
note, the renal extraction of this radiotracer is 100% 
and RBF obtained by 13N-ammonia demonstrated an 
excellent correlation when compared to the reference 
standard H215O [56].  
Renal Inflammation Molecular Imaging 
A recent study evaluated the value of 18F-FDG 
for autosomal dominant polycycstic kidney disease in 
30 individuals and revealed a high diagnostic 
accuracy in detecting renal or hepatic cyst infections. 
Highlighting the potential of guiding therapy, 
baseline 18F-FDG PET/CT led to change in 
antiobiotics use in up to 63% of the patients [57]. 
18F-FDG, however, is rather nonspecific for 
inflammation imaging. 68Ga-Pentixafor targeting the 
C-X-C motif chemokine receptor 4 (overexpressed on 
leucocytes) has been investigated in patients with 
complicated urinary tract infections in combination 
with rMRI. Leukocyte infiltration was identified by 
areas of CXCR4 upregulation compared with 
unaffected parenchyma in PET, corresponding to 
areas with increased cell density in rMRI, which was 
further validated by ex vivo analysis. As such, 
combined PET/rMRI data revealed the potential of 
non-invasive detection of leukocytes in renal 
allografts [16] (Figure 6).  
 
 
Figure 3. First in-vivo 18F-Fluorodeoxysorbitol (18F-FDS) images in a healthy volunteer. Dynamic axial, coronal and sagittal images (left) showed rapid radiotracer accumulation in 
the renal cortex. A time–activity curve (right) obtained by dynamic PET imaging. Three-dimensional volumes of interest were placed on the outer layer (corresponding to the cortex, green) 
as well as inner layer (red) corresponding to the medulla [14]. 






Figure 4. 11C-para-Aminobenzoic acid (11C-PABA) PET/CT renal imaging in a healthy subject. After a vascular phase after 22 seconds after injecvtion, the cortical uptake was 
evident within 2.7 and 3.2 minutes, with maximal parenchymal uptake in the renal cortex. The excretory phase was seen after 9 minutes indicating the maximal uptake in the pelvicalyceal 
system. Modified from Ruiz-Bedoya et al [12], copyright 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc. 
 
Figure 5. Renal blood flow assessed by H215O PET of a healthy subject (upper row) vs. subject with moderate renal disease (lower row). Left: transverse view, right: coronal views. Modified from 
Alpert et al [49], copyright 2002 by the Society of Nuclear Medicine and Molecular Imaging, Inc. 
 
Molecular Imaging of Renal Cell Carcinoma 
Assessment of primary renal tumors is 
challenging, mainly due the high physiological 
uptake seen with imaging agents such as 18F-FDG or 
somatostatin receptor-targeting 68Ga-DOTA-D-Phe- 
Tyr3-octreotide (DOTATOC) or 68Ga-DOTA-D-Phe- 
Tyr3-octreotate (DOTATATE) [58]. The United States 
Food and Drug Administration (FDA) approved 
radiotracer Anti-1-amino-3-[18F]-flurocyclobutane-1- 
carboxylic acid (anti-18F-FACBC) assessing the 
upregulation of increased amino acid metabolism, 
however, has almost no renal excretion. Spearheaded 
by Schuster et al, six patients afflicted with renal 
lesions were investigated and correlation with 
histology revealed that amino acid transport 
compared with renal cortex is elevated in renal 
papillary cell carcinoma but not in clear cell renal cell 
carcinoma (ccRCC) [59]. Similar results have been 
gained from a rapid autopsy study investigating the 
second-generation prostate-specific membrane 
antigen (PSMA) agent 18F-DCFPyL demonstrating an 
accurate detection of sites of metastatic ccRCC [60]. In 
addition, lymph node diseases along with photopenic 
defects in the kidneys have been recently reported in a 
biopsy-proven oncocytoma using 18F-DCFPyL [61]. 
The 68Ga-labeled imaging agent PSMA-11 has 
received FDA approval just recently, which makes 
PSMA PET imaging more widely available for 
potential use in RCC. Nonetheless, such 





radiopharmaceuticals have been primarily 
investigated for assessing tumor burden in patients 
afflicted with RCC, whereas their use for renal 
functional imaging is rather limited [40].  
Clinical Applications 
Although the use of PET can be limited by the 
installed base and high synthesis and maintenance 
costs, there are definite clinical applications of new 
renal PET radiotracers. For example, the low radiation 
exposures may lead to use in pediatrics, and the 
intrinsic advantages of PET may make these agents 
useful for those settings where an accurate renal 
functional assessment is required. Measurement of 
renal function in children can be difficult with 
noninvasive techniques because changes in body size 
and creatinine excretion can make creatinine clearance 
less reliable. In addition, children often have ureteral 
obstruction and anatomic abnormalities which may 
not be well evaluated by convetional scintigraphy 
[18]. Although there are many hurdles to overcome, 
renal PET, with its anatomic information and high 
resolution, may address those issues.  
In pediatric nuclear medicine, nuclear medicine 
specialists are facing the dilemma of reducing both 
radiation exposure and scan time. According to an 
IAEA study of 133 institutions from 62 countries on 
pediatric renal scintigraphy, most of the institutions 
would in fact administer a higher activity as 
recommended. The authors noted that the sites may 
have prioritized a shorter scan time (balanced by 
higher injected activities) rather than reducing 
radiation exposure [62]. Given the higher count rates 
achieved with renal PET imaging relative to 
conventional scintigraphy, the administered activity 
could be significantly reduced for renal PET 
radiotracers while not sacrificing image quality or 
scan time. For example, Hofmann et al. typically 
administered 40 MBq of 68Ga-EDTA in adult patients, 
which results in approximately 1.6 mSv from the PET 
component and equates to approximately the 
exposure of 320 MBq of injected 99mTc-DTPA [11]. In 
addition, Ruiz-Bedoya et al. demonstrated that the 
effective dose of 11C-PABA was 1.6-fold lower than 
that of 99mTc-MAG3 in a murine data-based human 
dosimetry analysis. The CT component of the 
PET/CT would add additional radiation exposure to 
the patient, but this can be as low as 0.25 mSv with an 
ultralow dose CT and the limited field-of-view 
required for renal imaging [10-12]. As a result, renal 
PET minimizes radiation exposure, which is 
especially important for patients in need for an 
accurate assessment of renal function, e.g. while 
under chemotherapy or to monitor outcome after 
kidney transplantation [9, 15, 18]. Renal PET could 
also be an alternative to CT-based urography to 
investigate urinary tract obstruction, especially for 




Figure 6. PET and MR of acute renal cyst infection. MR (top) and PET/CT images (bottom) of patient with kidney transplantation due to autosomal-dominant 
polycystic kidney disease and suspected complicated urinay tract infection. Imaging revealed upregulated CXCR4 expression in 2 cysts (white arrow) showing renal cyst infection. 
Corresponding MRI confirms a cyst with thick wall (T2-weighted MRI, red arrow) and apparent diffusion coefficient (ADC) reduction in both areas, consistent with PET findings. Allograft in 
right lower abdomen, however, shows no signs of infection with low homogeneous 68Ga-Pentixafor signal. MRI shows linear ADC reduction and volume loss, consistent with scarring at upper 
pole. MIP = maximum-intensity projection. Modified from Derlin et al [16], copyright 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc. 





Future perspectives of PET in the field of 
nephro-urology 
Identifying high-risk cancer patients for later 
nephrotoxicity under anti-tumor regimens 
Recent years have also seen an expanded use of 
renal radionuclide SPECT imaging to identify patients 
which may have renal functional decline after 
multiple cycles of endoradiotherapies. There has been 
an expansion of the use of receptor radionuclide 
therapy (PRRT) in neuroendocrine tumors using 
somatostatin analogs labeled with beta-emitting 
radionuclides [63]. However, PRRT causes an 
impairment of renal function even years after 
initiation of therapy and, therefore, pre-therapeutic 
and serial measurements of kidney function have 
been recommended [64]. Of note, serum 
creatinine-based GFR estimates are insensitive to 
early toxicity and underestimate renal impairment in 
12% of subjects after PRRT as compared to GFR 
measured by 99mTc-DTPA [65-67]. Although renal 
irradiation from PRRT is most likely to be caused by 
uptake of radiolabeled somatostatin analogues in the 
proximal tubules, 99mTc-MAG3 reflecting tubular 
function could not identify high-risk patients with a 
late onset of renal failure [67]. Furthermore 
alpha-emitters (such as 223Ra and 225At) are now being 
used clinically, and their higher mean energy 
deposition and shorter range in tissue relative to beta 
radiation may allow for increased therapeutic efficacy 
with minimal side effects in normal tissue [68]. In this 
regard, Kratochwil et al. reported on two patients 
afflicted with metastatic prostate cancer, who received 
225Ac-PSMA [69], while Makvandi et al. observed 
increased renal toxicity with 225Ac and 213Bi in 
preclinical studies [70]. Not surprisingly, renal 
toxicity with 213Bi-DOTATATE for treatment of 
neuroendocrine tumors has also been reported [71]. In 
addition, a substantial portion of prostate cancer 
patients scheduled for radioligand therapy with 
177Lu-prostate-specific membrane antigen (PSMA) 
also develop renal decline [72]. Thus, given the 
increased use of endoradotherapies for various 
cancers, PET agents for renal function may be 
superior for kidney outcome prediction when 
compared to clinical biomarkers of renal decline or 
conventional SPECT imaging. Beyond such nuclear 
medicine therapies, kidneys are also prone to damage 
caused by iodine contrast agents and chemotherapy. 
Thus, PET agents such as Re(CO)3(18F-FEDA) and 
18F-PFH, which reflect proximal tubular secretion, 
may also provide a surrogate marker of short- and 
long-term renal damage under chemotherapeutic 
regimens [9].  
Theranostics and organ network analyses in 
nephrology and urology 
The theranostic concept in oncology is based on 
diagnostic molecular imaging, followed by an 
individually tailored treatment decision using the 
identical or similar therapeutic radiotracer [58]. In 
nephro-urology, targeted and timed therapeutic 
concepts could also be envisaged for clinical 
applications for the kidneys. Such an image-guided 
renoprotective strategy would identify dysregulation 
of the target mechanism in the kidneys (e.g. 
upregulation of inflammatory-related mediators in 
urinary tract infections), which indicates risk for 
adverse outcome. This may trigger targeted therapy 
assessing the identical target on a subcellular level in 
order to achieve favourable renal outcome. For 
instance, receptor blockade of CXCR4 using 
AMD-3100 increased bladder capacity and 
hyperexcitability in bladder-inflammed Wistar rats 
relative to controls [73]. As such, an 
inflammation-targeted read-out of the urinary tract 
system by using 68Ga-Pentixafor may identify the 
most suitable time-point for treatment initiation, 
which in turn may increase therapeutic efficacy 
(Figure 7). In addition, the baseline-derived 
radiotracer signal may be used as a predictor of 
outcome with defined endpoints such as major 
adverse renal events (MARE).  
In uro-oncology, PSMA-PET/CT assists in 
identifying prostate cancer patients which are suitable 
for PSMA-based radioligand therapy (RLT). This 
theranostic concept is currently penetrating the 
clinical arena, mainly due favorable results of recent 
major prospective trials. First, the phase 2 LuPSMA 
trial reported on progressive metastatic 
castration-resistant prostate cancer patients that have 
been previously treated with antiandrogens and 
taxane-based chemotherapy. RLT demonstrated high 
response rates and low toxic effects with grade 3 or 4 
thrombocytopenia in 13% of the patients [74]. These 
favorable results have been further confirmed in the 
TheraP trial reporting on higher PSA response and 
fewer grade 3 or 4 adverse events of RLT when 
compared with cabazitaxel [75]. The VISION trial 
(NCT03511664) will assess the outcome of patients 
treated with RLT in addition to best supportive/best 
standard of care versus patients treated with best 
supportive/best standard of care alone [76]. The 
LuPARP trial will investigate RLT in combination 
with the poly(ADP-ribose) polymerase (PARP) 
inhibitor Olaparib (NCT03874884) [77], whereas the 
PRINCE trial will investigate favorable effects of 
PSMA-targeted therapy with the PD1-checkpoint 
inhibitor pembrolizumab (NCT03658447) [78]. Results 
of these trials will further refine the role of 





theranostics in men afflicted with prostate carcinoma 
in various clinical scenarios.  
As alluded to earlier, PSMA-targeting imaging 
agents have also been investigated for potential use in 
RCC. In this regard, 16 patients with suspicion for 
ccRCC have been scanned with 68Ga-labeled PSMA 
PET/CT and 75% of the patients demonstrated avid 
primary lesions, with the majority of ccRCC subtype. 
Of note, in 42% of the cases, 68Ga-PSMA PET/CT led 
to change in management, due to the identification of 
new sites of suspected metastases and synchronous 
primaries [79]. Beyond its potential role in guiding 
clinical management, PSMA may also represent a 
promising therapeutic target in a theranostic setting. 
First, given the increased intrarenal tumor 
neovasculature which is tightly linked to increased 
PSMA expression [80], PSMA imaging may allow for 
patient selection for antiangiogenic therapies. These 
considerations are further fueled by recent reports of a 
prospective trial investigating the beneficial effects of 
a combination of an immune checkpoint inhibitor 
with a VEGF-targeted antiangiogenic drug. The anti–
programmed death ligand 1 (PD-L1) antibody 
avelumab was combined with the highly selective 
vascular endothelial growth factor (VEGFR) inhibitor 
axitinib in patients with previously untreated 
advanced RCC. When compared with sunitinib, 
progression-free survival was significantly prolonged 
when used in first-line treatment, but grade 3 adverse 
events still occurred in 71% receiving such a 
combination treatment [81]. Multiple trials of 
antiangiogenic drugs targeting the VEGFR pathway 
are currently ongoing and resistance to antiangiogenic 
therapy in clinical practice seems to be a critical issue 
for future developments in the field. Therefore, 
PSMA-directed imaging could not only help to 
increase therapeutic efficacy by selecting individuals 
with increased intrarenal tumor-driven angiogenesis 
but may also avoid unnecessary treatments or led to 
early termination of VEGFR-interacting drugs, e.g. 
once the signal has been dissipated on restaging 
under antiangiogenic regimens [82]. Second, 
aggressive RCC subtypes with increased PSMA 
expression on the tumor cell surface may also allow 
for a theranostic approach by identifying potential 
therapy candidates by 68Ga/18F-PSMA imaging 
followed by 177Lu-PSMA treatment [83]. For instance, 
Spatz et al evaluated the relationship between PSMA 
expression and clinicopathological features in 257 
patients with RCC, ccRCC, papillary RCC and 
chromophobe RCC. Of note, 82.5% of ccRCC and 
71.4% of chromophobe RCC specimens demonstrated 
increased PSMA expression, whereas only 13.6% of 
papillary RCC expressed PSMA. Most importantly, 
the association of PSMA expression with overall 
survival was superior when compared to established 
clinical parameters, including tumor grade, primary 
and metastasis stage [84]. In addition, RCC still has a 
poor prognosis, despite recent efforts of applying 
novel immune checkpoint inhibitors [85]. If PSMA 
expression, however, increases with more aggressive 
disease, one may speculate that the signal derived by 
PSMA-targeting PET will not be diminished, even in 
highly advanced disease [84]. Moreover, in 
chromophobe RCC, where therapeutic options are 
still rather limited, PSMA was also upregulated in the 
majority of the cases, supporting the notion of 
PSMA-based theranostics in this rare phenotype [83]. 
Last, efficacy of immunotherapy could be further 
enhanced by combination treatments with 
PSMA-targeting RLT in PSMA-positive RCC 
patients [51].  
 
 
Figure 7. Targeted and timed therapy for clinical applications in nephrology by using molecular imaging (theranostics). By using dedicated radiotracers, e.g. to assess 
inflammation in the kidneys, a targeted therapy for an on-peak reperative intervention (anti-inflammatory therapy) could be initiated at the maximum of target expression. Both the diagnostic 
and matched therapeutic agent use the identical or at least comparable molecular pathways. Such a molecular imaging-guided treatment strategy for identifying the ideal time point for on-peak 
treatment may prevent adverse renal remodeling. In addition, a follow-up PET/CT to re-evaluate treatment efficacy can be considered. The derived imaging signal at baseline may be also a 
useful predictor for outcome, with defined endpoints such as major adverse renal events (MARE). Moreover, as PET allows for a whole-body non-invasive read-out, interactions of the kidneys 
with other organs, such as spleen, bone marrow or vessel walls could be conducted. 





Apart from applying theranostics in nephrology 
and urology, interactions with remote organs, such as 
the vessels or the spleen, could be also pursued by 
whole-body molecular imaging, potentially allowing 
for non-invasive analyses of kidney-organ networks 
[86]. Long-bore cameras with lager field-of-views and 
recent installations of whole-body PET scanners will 
further enable for such crosstalk investigations along 
various kidney-organ axes (Figure 7) [87]. Such 
investigations may be of interest in the field of 
inflammatory renal molecular imaging, e.g. to assess 
the signal in organs serving as reservoirs of 
inflammatory cells, such as the bone marrow or 
kidneys. Other aspects may also include kidney 
interactions with the molecular brain signal, 
potentially allowing for a simultaneous read-out of 
renal and brain function. Further improving the 
PET-based read-out of the kidneys, dedicated 
protocols could be applied, e.g. by furosemide 
injection enabling for sufficient excretion of the 
radiotracer prior to the scan [16]. 
Conclusions 
Despite the development of CT, MRI, and 
ultrasound techniques for evaluating the kidney, 
renal scintigraphy is still frequently requested in 
clinical practice. In a manner similar to brain, cardiac, 
and tumor molecular imaging, renal radionuclide 
imaging is beginning a shift from SPECT to PET. The 
GFR-reflecting radiotracer 18F-FDS can be synthesized 
from 18F-FDG in a one-step synthesis and thus, 
18F-FDS would be available at virtually every PET 
practice with access to a cyclotron. In addition, the 
relatively long half-life of 18F renders it as a potential 
agent for clinical trials, in particular in pediatric 
populations as it has significantly less radiation 
exposure compared to SPECT equivalents [9, 13, 14]. 
Moreover, inflammatory-targeting radiotracers have 
been investigated for renal applications, e.g. in 
patients with urinary tract infections. This may open 
avenues for timed and targeted therapies at the 
maximum of the PET-derived target expression, 
potentially transferring the concept of theranostics 
from oncology to nephron-urology. Moreover, given 
the capability of PET for a whole-body systemic 
read-out, such a molecular image-guided strategy 
could be used for a wholistic benefit not only 
maximizing outcome in the target organ (kidneys) but 
also in remote organs. Nonetheless, whole-body PET 
scanners are currently sparsely available. Commonly 
used hybrid devices with 16 cm field of view may still 
allow for assessing split renal function and clearance 
measurements. In addition, a more widespread 
adoption of PET radiotracers for renal applications is 
needed, preferably in prospective clinical trials. 
Favorable results relative to conventional SPECT 
would also pave the way for FDA approval of renal 
functional PET radiotracers, which would then lead to 
an increased clinical use of PET for this purpose. 
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